PPP2CA and acute myeloid leukemia: In AML, our group and others showed that the hyperphosphorylation of PP2A-C and consequent inactivation is observed in 78% of AML patients, along with high levels of PP2A endogenous inhibitors SET and CIP2A [68,79,80,81].